Long–Term Renal Outcomes after Cisplatin Treatment | Zendy

Sheron Latcha | Zendy; Edgar A. Jaimes | Zendy; Sujata Patil | Zendy; Ilya Glezerman | Zendy; Swati Mehta | Zendy; Carlos D. Flombaum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long–Term Renal Outcomes after Cisplatin Treatment

Author(s) -

Sheron Latcha,

Edgar A. Jaimes,

Sujata Patil,

Ilya Glezerman,

Swati Mehta,

Carlos D. Flombaum

Publication year - 2016

Publication title -

clinical journal of the american society of nephrology

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.08070715

Subject(s) - medicine , cisplatin , renal function , nephrotoxicity , percentile , creatinine , urology , continuous variable , retrospective cohort study , incidence (geometry) , toxicity , chemotherapy , oncology , statistics , physics , mathematics , optics

Nephrotoxicity remains the dose-limiting side effect of cisplatin, an effective chemotherapeutic agent with applications across diverse tumor types. This study presents data on renal outcomes across multiple tumor types in 821 adults. We report on incidence of AKI, initial and long-term changes in eGFR after cisplatin, and relationships between cumulative dose, initial eGFR, age, sex, and long-term renal function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research